Kinetics of circulating KSHV DNA burden and lymphocyte subsets during a 3-year follow-up period in the patient with multicentric Castleman disease.

Changes in KSHV DNA load in PBMCs (A), peripheral blood CD19/CD20⁺ B cell counts (B), CD4⁺ T-cell counts (C), and CD4⁺/CD8⁺ T-cell ratio (D) in an HIV-1– infected patient with multicentric Castleman disease during treatment with cidofovir, antihuman IL-6 monoclonal antibody (BE-8), and cytotoxic therapy (horizontal arrows) and after a single dose of anti-CD20 monoclonal antibody (shaded area). Throughout most of the study period, the patient was under effective, highly active antiretroviral therapy.